4th Jan 2022 10:51
Renalytix PLC - London-based diagnostics company focused on kidney health - Says it has partnered with the American Diabetes Association on a programme concerning the kidney health of patients with type 2 diabetes in the US. Renalytix said the programme intends to drive early detection and risk-informed care delivery to delay disease progression, reduce dialysis starts, and improve the overall health of chronic kidney disease patients with diabetes.
Current stock price: 631.00 pence, up 1.8% on Tuesday in London
By Heather Rydings; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc